STXS — Stereotaxis Share Price
0.000.00%
Last trade - 00:00- $169.38m
- $162.51m
- $26.92m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 27.86 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.29 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -98.48% | ||
| Return on Equity | -226.13% | ||
| Operating Margin | -91.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 26.63 | 35.02 | 28.15 | 26.77 | 26.92 | 33.23 | 53.35 | -1.41% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
Directors
- David Fischel CHM (34)
- Kimberly Peery CFO (52)
- David Benfer LED (74)
- Myriam Curet DRC (64)
- Nathan Fischel DRC (65)
- Ross Levin IND (37)
- Arun Menawat IND (66)
- Robert Messey IND (75)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 13th, 1990
- Public Since
- August 12th, 2004
- No. of Shareholders
- 395
- No. of Employees
- 139
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 85,979,662
- Address
- 710 N Tucker Blvd, Ste 110, ST. LOUIS, 63101
- Web
- https://www.stereotaxis.com/
- Phone
- +1 3146786100
- Contact
- Kimberly Peery
- Auditors
- Ernst & Young LLP
Upcoming Events for STXS
Q1 2025 Stereotaxis Inc Earnings Call
Stereotaxis Inc Annual Shareholders Meeting
Stereotaxis Inc Annual Shareholders Meeting
Q2 2025 Stereotaxis Inc Earnings Release
Similar to STXS
Acme United
NYSE MKT
Alpha Pro Tech
NYSE MKT
Catheter Precision
NYSE MKT
Electromed
NYSE MKT
Infusystem Holdings
NYSE MKT
FAQ
What is the Stereotaxis share price?
As of Today at 23:26 UTC, shares in Stereotaxis are trading at $1.97. This share price information is delayed by 15 minutes.
How has the Stereotaxis share price performed this year?
Shares in Stereotaxis last closed at $1.97 and the price had moved by -16.17% over the past 365 days. In terms of relative price strength the Stereotaxis share price has underperformed the S&P500 Index by -22.62% over the past year.
What are the analyst and broker recommendations for Stereotaxis?
The overall consensus recommendation for Stereotaxis is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Stereotaxis dividend yield?
Stereotaxis does not currently pay a dividend.
Does Stereotaxis pay a dividend?
Stereotaxis does not currently pay a dividend.
When does Stereotaxis next pay dividends?
Stereotaxis does not currently pay a dividend.
How do I buy Stereotaxis shares?
To buy shares in Stereotaxis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Stereotaxis?
As of the previous close price of $1.97, shares in Stereotaxis had a market capitalisation of $169.38m.
Where are Stereotaxis shares listed?
Here are the trading details for Stereotaxis:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: STXS
What kind of share is Stereotaxis?
Based on an overall assessment of its quality, value and momentum Stereotaxis is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Stereotaxis share price forecast for 2025?
The analyst consensus target price for shares in Stereotaxis is $4.50. That is 128.43% above the last closing price of $1.97.
Analysts covering Stereotaxis currently have a consensus Earnings Per Share (EPS) forecast of -$0.27 for the next financial year.
Find out moreWhat is the trend in the Stereotaxis share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Stereotaxis. Over the past six months, its share price has outperformed the S&P500 Index by +9.86%.
As of the last closing price of $1.97, shares in Stereotaxis were trading -4.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Stereotaxis PE Ratio?
The Stereotaxis PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.97.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Stereotaxis?
Stereotaxis' management team is headed by:
- David Fischel - CHM
- Kimberly Peery - CFO
- David Benfer - LED
- Myriam Curet - DRC
- Nathan Fischel - DRC
- Ross Levin - IND
- Arun Menawat - IND
- Robert Messey - IND